Relevance of BET Family Proteins in SARS-CoV-2 Infection
Open Access
- 30 July 2021
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 11 (8) , 1126
Abstract
The recent pandemic we are experiencing caused by the coronavirus disease 2019 (COVID-19) has put the world’s population on the rack, with more than 191 million cases and more than 4.1 million deaths confirmed to date. This disease is caused by a new type of coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A massive proteomic analysis has revealed that one of the structural proteins of the virus, the E protein, interacts with BRD2 and BRD4 proteins of the Bromodomain and Extra Terminal domain (BET) family of proteins. BETs are essential to cell cycle progression, inflammation and immune response and have also been strongly associated with infection by different types of viruses. The fundamental role BET proteins play in transcription makes them appropriate targets for the propagation strategies of some viruses. Recognition of histone acetylation by BET bromodomains is essential for transcription control. The development of drugs mimicking acetyl groups, and thereby able to displace BET proteins from chromatin, has boosted interest on BETs as attractive targets for therapeutic intervention. The success of these drugs against a variety of diseases in cellular and animal models has been recently enlarged with promising results from SARS-CoV-2 infection studies.Keywords
Funding Information
- Ministry of Science, Innovation and Universities (MICIU), Spain (PGC2018-094232-B-I00)
- Regional government from Andalusia (CV20-93141)
This publication has 256 references indexed in Scilit:
- Current Understanding of the Role of the Brd4 Protein in the Papillomavirus LifecycleViruses, 2013
- Reactivation of Latent HIV-1 by Inhibition of BRD4Cell Reports, 2012
- Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activationNature Cell Biology, 2011
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaNature, 2011
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- Selective inhibition of BET bromodomainsNature, 2010
- The chromatin-targeting protein Brd2 is required for neural tube closure and embryogenesisBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2009
- Double bromodomain‐containing gene Brd2 is essential for embryonic development in mouseDevelopmental Dynamics, 2009
- The Double Bromodomain Proteins Brd2 and Brd3 Couple Histone Acetylation to TranscriptionMolecular Cell, 2008